[ESMO 2026] Lee Su-jin, Executive Director at SillaJen: “BAL0891 maintains complete remission for 7 months”
Predicted impact: Medium
Conference clinical data for BAL0891: complete remission kept 7 months; small-revenue biotech, so data can matter.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.